BUSINESS WIRE

Dabigatran Etexilate Shows Greater Reductions Than Warfarin in Stroke in Patients with Atrial Fibrillation across All Stroke Risk Groups

Loading media player...
Dr. Jonas Oldgren comments on the RE-LY CHADS2 subgroup analysis (Video: Business Wire)

Embed